Biomarker portfolio

OGT is developing a portfolio of diagnostic biomarkers into “best-in-class” clinical diagnostic tests. For colorectal cancer and systemic lupus erythematosus (SLE) we plan on working with partners for the commercialisation of these tests. For prostate cancer, OGT is planning to develop and commercialise this diagnostic test via clinical laboratories in key markets. 

• Sign up to E-News

  Get the latest information in your area of interest.

  Sign up now
• Cancer NGS Webinar

  Effective cancer sequencing and analysis strategies

  Register now